48,163 research outputs found

    Observation of Terahertz Radiation via the Two-Color Laser Scheme with Uncommon Frequency Ratios

    Get PDF
    In the widely-studied two-color laser scheme for terahertz (THz) radiation from a gas, the frequency ratio of the two lasers is usually fixed at ω2/ω1=\omega_2/\omega_1=1:2. We investigate THz generation with uncommon frequency ratios. Our experiments show, for the first time, efficient THz generation with new ratios of ω2/ω1=\omega_2/\omega_1=1:4 and 2:3. We observe that the THz polarization can be adjusted by rotating the longer-wavelength laser polarization and the polarization adjustment becomes inefficient by rotating the other laser polarization; the THz energy shows similar scaling laws with different frequency ratios. These observations are inconsistent with multi-wave mixing theory, but support the gas-ionization model. This study pushes the development of the two-color scheme and provides a new dimension to explore the long-standing problem of the THz generation mechanism.Comment: 6 pages, 3 figure

    The convergence analysis and error estimation for unique solution of a p-Laplacian fractional differential equation with singular decreasing nonlinearity

    Get PDF
    © 2018, The Author(s). In this paper, we focus on the convergence analysis and error estimation for the unique solution of a p-Laplacian fractional differential equation with singular decreasing nonlinearity. By introducing a double iterative technique, in the case of the nonlinearity with singularity at time and space variables, the unique positive solution to the problem is established. Then, from the developed iterative technique, the sequences converging uniformly to the unique solution are formulated, and the estimates of the error and the convergence rate are derived

    Observation of momentum-confined in-gap impurity state in Ba0.6_{0.6}K0.4_{0.4}Fe2_2As2_2: evidence for anti-phase s±s_{\pm} pairing

    Get PDF
    We report the observation by angle-resolved photoemission spectroscopy of an impurity state located inside the superconducting gap of Ba0.6_{0.6}K0.4_{0.4}Fe2_2As2_2 and vanishing above the superconducting critical temperature, for which the spectral weight is confined in momentum space near the Fermi wave vector positions. We demonstrate, supported by theoretical simulations, that this in-gap state originates from weak non-magnetic scattering between bands with opposite sign of the superconducting gap phase. This weak scattering, likely due to off-plane Ba/K disorders, occurs mostly among neighboring Fermi surfaces, suggesting that the superconducting gap phase changes sign within holelike (and electronlike) bands. Our results impose severe restrictions on the models promoted to explain high-temperature superconductivity in these materials.Comment: 8 pages, 5 figures. Accepted for publication in Physical Review

    Anisotropic Magnetoresistance in Charge-Ordering Na0.34(H3O)0.15CoO2Na_{0.34}(H_3O)_{0.15}CoO_2:Strong Spin-Charge Coupling and Spin Ordering

    Full text link
    Angular-dependent in-plane magnetoresistance (AMR) for single crystal Na0.34(H3O)0.15CoO2Na_{0.34}(H_3O)_{0.15}CoO_2 with charge ordering is studied systematically. The anisotropic magnetoresistance shows a twofold symmetry at high temperature with rotating H in the Co-O plane, while a sixfold symmetry below a certain temperature (TρT_\rho). At TρT_\rho, the symmetry of AMR changes from twofold to fourfold with rotating magnetic field (H) in the plane consisting of the current and c-axis. The variation of AMR symmetry with temperature arises from the subtle changes of the spin structure. These results give a direct evidence for the itinerant electrons directly coupled to the localized spins.Comment: 4 pages, 4 figure

    Antiproliferative and apoptotic effects of angelicin in highly invasive prostate cancer cells

    Get PDF
    Purpose: To demonstrate the anti-proliferative activity of angelicin against human prostate cancer (PC- 3) cells and to evaluate its mechanismMethods: MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was used to assess the anticancer activity (growth inhibition) of angelicin in PC-3 cells. Fluorescence microscopy using Hoechst  33258 staining and inverted phase microscopy was employed to evaluate the effect of angelicin on nuclear morphology. Flow cytometry, using propidium iodide, was employed to study cell cycle-related effects of angelicin. Apoptosis induction by angelicin was examined by annexin V/PI assay.Results: Angelicin induced potent growth inhibitory effects in human prostate cancer (PC-3) cells in a  dose-dependent manner. Angelicin-treated cells exhibited chromatin condensation which implied an early  apoptotic event. Inverted phase microscopy revealed that reduction of cell population occurred with increase in the angelicin dose. Flow cytometry results showed that angelicin induced cell cycle arrest in the sub-G1 phase. Angelicin induced both early and late apoptosis in PC-3 cells following a dose-dependent pattern.Conclusion: Angelicin inhibits the growth of PC-3 human prostate cancer cells in vitro by inducing early and late apoptosis, cell cycle arrest and chromatin condensation

    Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients

    Get PDF
    Background: Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSCC) are two of the most common subtypes of non-small cell lung cancer (NSCLC), with high mortality rates and rising incidence worldwide. Ferroptosis is a mode of programmed cell death caused by lipid peroxidation, the accumulation of reactive oxygen species, and is dependent on iron. The recent discovery of ferroptosis has provided new insights into tumor development, and the clinical relevance of ferroptosis for tumor therapy is being increasingly appreciated. However, its role in NSCLC remains to be explored. Methods: The clinical and molecular data for 1727 LUAD and LUSCC patients and 73 control individuals were obtained from the Gene Expression Omnibus (GEO) database and the Cancer Genome Atlas (TCGA) database. Gene expression profiles, copy number variations and somatic mutations of 57 ferroptosis-related genes in 1727 tumor samples from the four datasets were used in a univariate Cox analysis and consensus clustering analysis. The biological signatures of each pattern were identified. A ferroptosis score was generated by combining the univariate Cox regression analysis and random forest algorithm followed by principal component analysis (PCA) and further investigated for its predictive and therapeutic value in LUAD and LUSCC. Results: The expression of 57 ferroptosis-related genes in NSCLC patients differed significantly from that of normal subjects. Based on unsupervised clustering of ferroptosis-related genes, we divided all patients into three ferroptosis expression pattern groups, which showed differences in ferroptosis-associated gene expression patterns, immune cell infiltration levels, prognostic characteristics and enriched pathways. Using the differentially expressed genes in the three ferroptosis expression patterns, a set of 17 ferroptosis-related gene prognostic models was established, which clustered all patients in the cohort into a low score group and a high score group, with marked differences in prognosis (p < 0.001). The high ferroptosis score was significantly associated with positive response to radiotherapy (p < 0.001), high T stage (p < 0.001), high N stage (p < 0.001) and high-grade tumor (p < 0.001) characteristics. Conclusions: The 17 ferroptosis-associated genes show great potential for stratifying LUAD and LUSCC patients into high and low risk groups. Interestingly, a high ferroptosis score in LUAD patients was associated with a good prognosis, whereas a similar high ferroptosis score in LUSCC patients was associated with a poor prognosis. Familiarity with the mechanisms underlying ferroptosis and its implications for the treatment of NSCLC, as well as its effect on OS and PFS, may provide guidance and insights in developing new therapeutic targets for NSCLC
    corecore